The Therapeutic Goods Administration (TGA) has issued an urgent warning regarding weight loss drugs, including Ozempic and Mounjaro, due to potential links to suicidal thoughts. The TGA cautioned that these GLP-1 receptor agonists may affect psychiatric behavior and oral contraceptive effectiveness. Patients are advised to report any mood changes, while health professionals should monitor for signs of depression or suicidal behavior. Statistics from TGA revealed numerous reports of suicidal ideation associated with these medications.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
